You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for New Drug Application (NDA): 203214


✉ Email this page to a colleague

« Back to Dashboard


NDA 203214 describes XELJANZ, which is a drug marketed by Pfizer and Pf Prism Cv and is included in three NDAs. It is available from two suppliers. There are four patents protecting this drug and two Paragraph IV challenges. Additional details are available on the XELJANZ profile page.

The generic ingredient in XELJANZ is tofacitinib citrate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.
Summary for 203214
Tradename:XELJANZ
Applicant:Pf Prism Cv
Ingredient:tofacitinib citrate
Patents:1
Pharmacology for NDA: 203214
Mechanism of ActionJanus Kinase Inhibitors
Suppliers and Packaging for NDA: 203214
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XELJANZ tofacitinib citrate TABLET;ORAL 203214 NDA Pfizer Laboratories Div Pfizer Inc 0069-1001 0069-1001-01 60 TABLET, FILM COATED in 1 BOTTLE (0069-1001-01)
XELJANZ tofacitinib citrate TABLET;ORAL 203214 NDA Pfizer Laboratories Div Pfizer Inc 0069-1002 0069-1002-01 60 TABLET, FILM COATED in 1 BOTTLE (0069-1002-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Nov 6, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 14, 2024
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION
Patent:⤷  Sign UpPatent Expiration:Dec 8, 2025Product Flag?Substance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:May 30, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 14, 2024
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION

Expired US Patents for NDA 203214

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-001 Nov 6, 2012 ⤷  Sign Up ⤷  Sign Up
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-001 Nov 6, 2012 ⤷  Sign Up ⤷  Sign Up
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-002 May 30, 2018 ⤷  Sign Up ⤷  Sign Up
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-002 May 30, 2018 ⤷  Sign Up ⤷  Sign Up
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-001 Nov 6, 2012 ⤷  Sign Up ⤷  Sign Up
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-001 Nov 6, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.